Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature

Autoimmunity Reviews

Volumn 10, Issue 8, 2011, Pages 460-463

  Ingegnoli, Francesca ^a   Favalli, Ennio Giulio ^a   Meroni, Pier Luigi ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti TNF blockers; Polymorphism; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALLELE; BIOLOGICAL THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; EFFECT SIZE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; JOINT INJURY; PATHOGENESIS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; GENETIC ASSOCIATION STUDIES; HUMANS; INDIVIDUALIZED MEDICINE; INFLAMMATION MEDIATORS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79957665365     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.01.010     Document Type: Review

References (41)

1. Lee D.M., Weinblatt M.E. Rheumatoid arthritis. Lancet 2001, 358:903-911.
2. Feldmann M., Brennan F.M., Foxwell B.M., Maini R.N. The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun 2001, 3:188-199.
3. Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344:907-916.
4. Skapenko A., Kalden J.R., Schulze-Koops H. Treatment of rheumatoid arthritis in the third millennium. Scand J Rheumatol 2001, 30:249-254.
5. Valesini G., Iannuccelli C., Marocchi E., Pascoli L., Scalzi V., Di F.M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 2007, 7:35-41.
6. Benucci M., Manfredi M., Puttini P.S., Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?. Autoimmun Rev 2010, 9:801-803.
7. Charles P., Elliott M.J., Davis D., Potter A., Kalden J.R., Antoni C., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999, 163:1521-1528.
8. Hyrich K.L., Watson K.D., Silman A.J., Symmons D.P. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006, 45:1558-1565.
9. Atzeni F., Antivalle M., Pallavicini F.B., Caporali R., Bazzani C., Gorla R., et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev 2009, 8:431-437.
10. Papagoras C., Voulgari P.V., Drosos A.A. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun Rev 2010, 9:574-582.
11. Caporali R., Sarzi-Puttini P., Atzeni F., Gorla R., Filippini M., Marchesoni A., et al. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 2010, 9:465-469.
12. Criswell L.A., Lum R.F., Turner K.N., Woehl B., Zhu Y., Wang J., et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004, 50:2750-2756.
13. Lee Y.H., Rho Y.H., Choi S.J., Ji J.D., Song G.G. Association of TNF-alpha -308G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2006, 27:157-161.
14. Cuchacovich M., Ferreira L., Aliste M., Soto L., Cuenca J., Cruzat A., et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 2004, 33:228-232.
15. Cuchacovich M., Soto L., Edwardes M., Gutierrez M., Llanos C., Pacheco D., et al. Tumour necrosis factor (TNF)alpha -308G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 2006, 35:435-440.
16. Guis S., Balandraud N., Bouvenot J., Auger I., Toussirot E., Wendling D., et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007, 57:1426-1430.
17. Marotte H., Pallot-Prades B., Grange L., Tebib J., Gaudin P., Alexandre C., et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 2006, 65:342-347.
18. Mugnier B., Balandraud N., Darque A., Roudier C., Roudier J., Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003, 48:1849-1852.
19. Padyukov L., Lampa J., Heimburger M., Ernestam S., Cederholm T., Lundkvist I., et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003, 62:526-529.
20. Seitz M., Wirthmuller U., Moller B., Villiger P.M. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007, 46:93-96.
21. Balog A., Klausz G., Gal J., Molnar T., Nagy F., Ocsovszky I., et al. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 2004, 71:274-280.
22. Rezaieyazdi Z., Afshari J.T., Sandooghi M., Mohajer F. Tumour necrosis factor a -308 promoter polymorphism in patients with rheumatoid arthritis. Rheumatol Int 2007, 28:189-191.
23. Fonseca J.E., Carvalho T., Cruz M., Nero P., Sobral M., Mourao A.F., et al. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 2005, 64:793-794.
24. Marotte H., Arnaud B., Diasparra J., Zrioual S., Miossec P. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2008, 58:1258-1263.
25. Maxwell J.R., Potter C., Hyrich K.L., Barton A., Worthington J., Isaacs J.D., et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008, 17:3532-3538.
26. Miceli-Richard C., Comets E., Verstuyft C., Tamouza R., Loiseau P., Ravaud P., et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2008, 67:478-484.
27. Pinto J.A., Rego I., Rodriguez-Gomez M., Canete J.D., Fernandez-Lopez C., Freire M., et al. Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. J Rheumatol 2008, 35:177-178.
28. O'Rielly D.D., Roslin N.M., Beyene J., Pope A., Rahman P. TNF-alpha-308G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J 2009, 9:161-167.
29. Pavy S., Toonen E.J., Miceli-Richard C., Barrera P., van Riel P.L., Criswell L.A., et al. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 2010, 69:1022-1028.
30. Fabris M., Di P.E., D'Elia A., Damante G., Sinigaglia L., Ferraccioli G. Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol 2002, 29:29-33.
31. Chatzikyriakidou A., Georgiou I., Voulgari P.V., Venetsanopoulou A.I., Drosos A.A. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology (Oxford) 2007, 46:1034-1035.
32. Toonen E.J., Coenen M.J., Kievit W., Fransen J., Eijsbouts A.M., Scheffer H., et al. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann Rheum Dis 2008, 67:1174-1177.
33. Kang C.P., Lee K.W., Yoo D.H., Kang C., Bae S.C. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005, 44:547-552.
34. van Heel D.A., Udalova I.A., De Silva A.P., McGovern D.P., Kinouchi Y., Hull J., et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. Hum Mol Genet 2002, 11:1281-1289.
35. Hohjoh H., Tokunaga K. Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-alpha gene (TNFA) promoter. Genes Immun 2001, 2:105-109.
36. Mullighan C.G., Fanning G.C., Chapel H.M., Welsh K.I. TNF and lymphotoxin-alpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. J Immunol 1997, 159:6236-6241.
37. Burmester G.R., Mariette X., Montecucco C., Monteagudo-Saez I., Malaise M., Tzioufas A.G., et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007, 66:732-739.
38. Tan R.J., Gibbons L.J., Potter C., Hyrich K.L., Morgan A.W., Wilson A.G., et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis 2010, 69:1029-1035.
39. Hassan B., Maxwell J.R., Hyrich K.L., Barton A., Worthington J., Isaacs J.D., et al. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology (Oxford) 2010, 49:43-47.
40. Liu C., Batliwalla F., Li W., Lee A., Roubenoff R., Beckman E., et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008, 14:575-581.
41. de Paz B., peri-Lopez M., Ballina-Garcia F.J., Prado C., Mozo L., Gutierrez C., et al. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis-association with clinical response to glucocorticoids. J Rheumatol 2010, 37:503-511.